

# Biopharmaceutics & Pharmacokinetics

fourth edition

**Leon Shargel, PhD**

Vice President and Technical Director  
National Association of Pharmaceutical Manufacturers  
Ronkonkoma, New York

Adjunct Associate Professor

School of Pharmacy  
University of Maryland  
Baltimore, Maryland

**Andrew Yu, PhD**

Associate Professor of Pharmaceutics  
Albany College of Pharmacy  
Albany, New York\*

\*Present affiliation

HFD-520 CDER, FDA, Rockville, MD.

(The contents of this book reflect the personal views of the authors and not that of the FDA.)

**McGraw-Hill**

Medical Publishing Division

New York St. Louis San Francisco Auckland Bogotá Caracas Lisbon London  
Madrid Mexico City Milan Montreal New Delhi San Juan  
Singapore Sydney Tokyo Toronto

SHIRE EX. 202  
KVK v. SHIRE  
IPR2018-00290

Copyright © 1999 by Appleton & Lange. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous editions copyright © 1993 by Appleton & Lange; copyright © 1985, 1980 by Appleton-Century-Crofts.

4 5 6 7 8 9 0 HPC/HPC 0 9 8 7 6 5 4 3 2 1

ISBN: 0-8385-0278-4 (domestic)

**Library of Congress Cataloging-in-Publication Data**

Shargel, Leon, 1941—

Applied biopharmaceutics and pharmacokinetics / Leon Shargel,

Andrew Yu. —4th ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-8385-0278-4 (case : alk. paper)

1. Biopharmaceutics. 2. Pharmacokinetics. I. Yu, Andrew B. C.,

1945— . II. Title

[DNLM: 1. Biopharmaceutics. 2. Pharmacokinetics. QV 38 S531a  
1999]

RM301.4.S52 1999

615'.7—dc21

DNLM/DLC

for Library of Congress

98-49079

Editor-in-Chief: Cheryl L. Mehalik

Production Service: York Production Services

Art Coordinator: Eve Siegel

Cover Design: Aimee Nordin

Illustrator: Wendy Beth Jackelow

ISBN: 0-8385-0321-7 (international)

Exclusive rights by The McGraw-Hill Companies, Inc. for manufacture and export. This book cannot be re-exported from the country to which it is consigned by McGraw-Hill. The International Edition is not available in North America.

# INTRODUCTION TO BIOPHARMACEUTICS AND PHARMACOKINETICS

---

## BIOPHARMACEUTICS

*Biopharmaceutics* considers the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption. Thus, biopharmaceutics involves factors that influence the (1) protection of the activity of the drug within the drug product, (2) the release of the drug from a drug product, (3) the rate of dissolution of the drug at the absorption site, and (4) the systemic absorption of the drug. Figure 2-1 is a general scheme describing this dynamic relationship.

The study of biopharmaceutics is based on fundamental scientific principles and experimental methodology. These methods must be able to assess the impact of the physical and chemical properties of the drug, drug stability and large scale production of the drug and drug product on the biological performance of the drug. Moreover, biopharmaceutics considers the requirements of the drug and dosage form in a physiological environment and the drug's intended therapeutic use and route of administration.

Studies in biopharmaceutics use both *in-vitro* and *in-vivo* methods. *In-vitro* methods are procedures employing test apparatus and equipment without involving laboratory animals or humans. *In-vivo* methods are more complex studies involving human subjects or laboratory animals. Some of these methods will be discussed in Chapter 5. Historically, pharmacologists evaluated the relative systemic drug availability *in vivo* after giving a drug product to an animal or human and then comparing specific pharmacologic, clinical, or possible toxic responses. For example, a drug such as isoproterenol causes an increase in heart rate when given intravenously but has no observable effect on the heart when given orally at the same dose level. Therefore, systemic drug availability may differ according to the route

metabolism

Figure 2-1. Scheme demonstrating the dynamic relationship between the drug, the drug product, and the pharmacologic effect.

of administration. In addition, the bioavailability (a measure of systemic availability of a drug) may differ from one drug product to another containing the same drug. This difference in drug bioavailability may be manifested by observing the difference in the therapeutic effectiveness of the drug products.

## PHARMACOKINETICS

*Pharmacokinetics* involves the kinetics of drug absorption, distribution, and elimination (ie, excretion and metabolism). The description of drug distribution and elimination is often termed *drug disposition*. The study of pharmacokinetics involves both experimental and theoretical approaches. The experimental aspect of pharmacokinetics involves the development of biological sampling techniques, analytical methods for the measurement of drugs and metabolites, and procedures that facilitate data collection and manipulation. The theoretical aspect of pharmacokinetics involves the development of pharmacokinetic models that predict drug disposition after drug administration. The application of statistics is an integral part of pharmacokinetic studies. Statistical methods are used for pharmacokinetic parameter estimation and data interpretation. Statistical methods are applied to pharmacokinetic models to determine data error and structural model deviations. Mathematics and computer techniques form the theoretical basis of many pharmacokinetic methods. Classical pharmacokinetics is a study of theoretical models focusing mostly on model development and parameterization.

## CLINICAL PHARMACOKINETICS

*Clinical pharmacokinetics* is the application of pharmacokinetic methods in drug therapy. Clinical pharmacokinetics involves a multidisciplinary approach to individually optimized dosing strategies based on the patient's disease state and patient-specific considerations. The study of clinical pharmacokinetics of drugs in disease states requires input from medical and pharmaceutical research. Table 2.1 is a list of 10 age-adjusted rates of death from 10 leading causes of death in the USA, 1993. The influence of many diseases on drug disposition is not adequately studied. Age, gender, genetic, and ethnic differences can also result in pharmacokinetic differences that may affect the outcome of drug therapy. The study of pharmacokinetic differences of drugs in various population groups is termed *population*

Accidents and others*	5	2.8
Pneumonia and influenza	6	1.6
Diabetes mellitus	7	1.2
HIV infections	8	6.3
Suicide	9	4.4
Homicide and legal intervention	10	3.8

\*Death due to adverse effects suffered as defined by CDC.

Source: CDC-MMWR (Morbidity and Mortality Weekly Report), March 1, 45:8, 1996.

*pharmacokinetics* (Sheiner and Ludden, 1992). Another important aspect of pharmacokinetics is *therapeutic drug monitoring* (TDM). When drugs with narrow therapeutic indices are used in patients, it is necessary to monitor plasma drug concentrations closely by taking periodic blood samples. The pharmacokinetic and drug analysis services necessary for safe drug monitoring are generally provided by the *clinical pharmacokinetic service* (CPKS). Some drugs frequently monitored are the aminoglycosides and anticonvulsants. Other drugs closely monitored are those used in cancer chemotherapy in order to minimize adverse side effects (Rodman and Evans, 1991).

## PHARMACODYNAMICS

*Pharmacodynamics* refers to the relationship between the drug concentration at the site of action (receptor) and pharmacologic response, including biochemical and physiologic effects that influence the interaction of drug with the receptor. The interaction of a drug molecule with a receptor causes the initiation of a sequence of molecular events resulting in a pharmacologic or toxic response. Pharmacokinetic-pharmacodynamic models are constructed to relate plasma drug level to drug concentration in the site of action and establish the intensity and time course of the drug. Pharmacodynamics and pharmacokinetic-pharmacodynamic models are discussed more fully in Chapter 19.

## TOXICOKINETICS AND CLINICAL TOXICOLOGY

*Toxicokinetics* is the application of pharmacokinetic principles to the design, conduct and interpretation of drug safety evaluation studies (Leal et al, 1993) and used in validating dose related exposure in animals. Toxicokinetic data aids in the interpretation of toxicologic findings in animals and extrapolation of the resulting data to humans. Toxicokinetic studies are performed in animals during preclinical drug development and may continue after the drug has been tested in clinical trials.



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.